

Sector: Pharmaceuticals

EPIC: ETX

Broker: Cornhill Asset Management

Status: AIM

Year End: 31/3

Mkt Cap: ~£30m



e-Therapeutics
systems biology drug discovery

e-Therapeutics aims to discover new therapies systematically using new systems biology tools, in order to alleviate treatable diseases where there are either no existing treatments or current treatments are unsatisfactory

Investment Highlights

- Global market for current product pipeline is estimated at £40billion
- Strong, highly skilled management and technical team
- e-therapeutics drug discovery platform more efficient than conventional R&D
- Ability to respond quickly to market opportunities
- Technology used lowers the risk of failure in clinical studies
- Existing development portfolio of drug candidates with commercially attractive properties

Market

- Pharmaceutical companies are increasingly looking to in-license early/mid stage compounds to address their weak new product pipeline and growth prospects
- Drug companies are now focussing on chemical entities, including off patent compounds with known toxicity profiles and repositioning them for alternative conditions

Competitive Edge

- e-Therapeutics seeks to develop proprietary technology and surrounding processes to discover drugs in commercially valuable therapeutics areas and develop them to a premium point of value before licensing to suitable partners
- Does not incur high costs for late stage drug development and regulatory approval
 - Is focused upon exploiting demand by pharmaceutical companies for Phase II validated drugs for substantial upfront milestone payments and sales royalties

Consultancy Service

- e-Therapeutics proprietary and patented in-silico technology can analyse drug compounds within the body
- In-silico technology predicts holistic effects of compounds within the body
 - Enables rapid and accurate efficacy and toxicity identifications at a lower cost
 - Projects with GlaxoSmithKline plc, Cambridge Laboratories Ltd, and Mylan Laboratories Inc.

Management

Professor Malcolm Young – Chief Executive Officer

One of eighteen scientists worldwide nominated by The Sunday Times as the "Brains behind the 21st Century". Director of the Complex Systems Group; and the Provost of the Faculty of Science, Agriculture and Engineering at Newcastle University. Previously Pro-Vice Chancellor for Strategic Development at Newcastle University

John Cordiner – Commercial and Financial Director

Over 15 years' international business experience, a chartered accountant and investment banker with Noble & Co where he specialised in the life sciences and oil and gas sectors

Royston Drucker – Medical Director

Extensive experience of drug development, having held senior positions in major pharmaceutical companies. Fellow of the Faculty of Pharmaceutical Medicine, founder of the Association for Human Pharmacology in the Pharmaceutical Industry, fellow of the Royal Society of Medicine, a member of the British Association of Pharmaceutical Physicians and a member of the Securities Institute

"We believe that Malcolm and his team, armed with the unique discovery platform e-Therapeutics has in place, have the power to generate substantial value for investors. Drug and clinical trials are already demonstrating the success of e-Therapeutics' offering, and the company has great prospects for long-term growth."

Alex Macpherson, Chief Executive, Katalyst Ventures.


The Company

e-Therapeutics applies their novel and systematic approach to three areas:

1. discovery of new drugs
2. discovering novel uses for existing drugs
3. analysis of the interactions between different drugs

Product Pipeline

- Focused on high prevalence conditions
- Intellectual Property rights - e-Therapeutics has 14 patents pending for drug compounds



e-Therapeutics Product Pipeline

